This page shows the latest flutemetamol news and features for those working in and with pharma, biotech and healthcare.
Although the last few years have seen a number of Alzeimer's diagnostics approved, among them GE Healthcare Vizamyl (flutemetamol) and Piramal's Neuraceq (florbetaben F18), research progress for a treatment
event. In addition GE Healthcare received a positive opinion for Vizamyl (flutemetamol) as a diagnostic for Alzheimer's disease.
18F) and GE Healthcare's Vizamyl (flutemetamol F18) on the market.
The Food and Drug Administration's (FDA) recommendation for Vizamyl (flutemetamol F 18 injection) means the drug, marketed by GE Healthcare, is the second brain imaging agent approved in the US
for the disease are in late-stage development, such as GE Healthcare's flutemetamol and Bayer's florbetaben.
The CMS may change its position given that competing PET imaging agents for Alzheimer's are coming through development, notably GE Healthcare's flutemetamol and Bayer's florbetaben, both of which
More from news
Approximately 1 fully matching, plus 5 partially matching documents found.
We're a leading healthcare strategic communications agency helping pharmaceutical companies adapt fast to improve the lives of patients and healthcare...